Trial Profile
A Phase II clinical trial to investigate the efficacy of ODM-203 in slowing the growth of solid cancerous tumours in patients in which FGFR changes in cancerous tumours have been detected
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2016
Price :
$35
*
At a glance
- Drugs AUR 109 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 28 Apr 2016 New trial record